HOME >> BIOLOGY >> NEWS
AAAS CEO Alan I. Leshner welcomes proposed Washington state legislation on stem cell research

WASHINGTON, D.C.-AAAS has welcomed efforts by Washington state legislators to pass a bill banning reproductive cloning in the state while allowing research on human embryonic stem cells.

In letters sent to two sponsors of the bill, Alan I. Leshner, the chief executive officer of AAAS and executive publisher of the journal Science, reaffirmed the association's position that cloning to extract stem cells from early-stage human embryos for research purposes "holds great promise." But he also noted that "the benefits will only be realized through carefully designed research" that is subject to appropriate ethical and legal oversight. And he reiterated that AAAS has endorsed a legal ban on any efforts to clone human embryos to produce babies.

Leshner's letter was faxed Monday 28 March 28 2005 as a committee of the Washington State Senate holds a hearing on the bill, which already has been approved by the state's House of Representatives. The letter was sent to state Rep. Shay Schual-Berke, a physician and sponsor of the bill in the House, and state Sen. Jeanne Kohl-Welles, a co-sponsor in the Senate who has a Ph.D. in sociology. Both are Democrats.

The bill includes some specific ethical guidelines, such as the patient's right to full disclosure and civil penalties for reproductive cloning.

Legislators in several states, including Maryland, have attempted to follow the lead of California in backing stem cell research that President George W. Bush restricted at the federal level in 2001. In Congress, the House leadership reportedly has agreed to allow a floor vote this session on a proposal to ease the federal restrictions and allow study of newer stem cell lines derived from embryos discarded by fertility clinics.

[For more information, read the full letter. ]


'"/>


29-Mar-2005


Page: 1

Related biology news :

1. Statement from Dr. Alan I. Leshner, CEO of AAAS, on the Kansas State Board of Education vote
2. AAAS CEO Alan I. Leshner urges US to continue collecting job data on women workers
3. AAAS CEO Alan I. Leshner registers strong concerns over suppression of science films
4. AAAS CEO Alan I. Leshner statement on the UN cloning debate
5. National Inventors Hall of Fame welcomes 2005 inductees
6. BioMed Central welcomes the new National Institutes of Health public access policy
7. Telemedicine initiative for sub-Saharan Africa: Pilot projects proposed
8. Major initiative proposed to address amphibian crisis
9. AIDS research agenda proposed
10. New model of p53 regulation proposed that suggests novel anticancer strategy
11. Mechanism proposed for link between RU-486 and fatal infections

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
Cached News: